Clinical Trials Sponsored by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Total 17 results

Gesellschaft fur Medizinische Innovation - Hamatologie...

Completed

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Multiple Myeloma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...

Terminated

Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines (TRACEII)

Ovarian Cancer

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...

Recruiting

National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Newly-diagnosed APL (de Novo or Therapy-related) | Relapsed APL

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...

Completed

Lenalidomide/Low-dose Dexamethasone in Combination With Continuous Oral Cyclophosphamide Compared to Lenalidomide/Low-dose Dexamethasone Combined With Single Cyclophosphamide Doses IV in Patients With Relapsed/Refractory Multiple Myeloma (MM_LEN_DEX_CY)

Multiple Myeloma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
Amgen

Completed

Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia (EUROPE)

Myelodysplastic Syndromes

France, Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)

Myelodysplastic Syndromes

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Completed

Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma (DSM XIII)

Multiple Myeloma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH

Terminated

SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment

Colorectal Carcinoma

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
Crolll Gmbh

Completed

Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation (Crescendo)

Chronic Myelogenous Leukemia (CML)

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
Celgene; Amgen

Terminated

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP (R²-DHAP)

Diffuse Large B-cell Lymphoma (DLBCL) | Burkitt Lymphoma (BL) | Follicular Lymphoma Grade III (FL III°) | Mantle Cell Lymphoma (MCL), Blastoid Variant | Aggressive Marginal Zone Lymphoma (MZL)

Germany
Heidelberg University
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Completed

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis (LEOMEX)

Primary Amyloidosis

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
iOMEDICO AG

Completed

Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment (PASO)

Metastatic Breast Cancer

Germany
Gesellschaft fur Medizinische Innovation - Hamatologie...
ClinAssess GmbH; Deutsche Klinik fuer Diagnostik

Completed

PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood

Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Unknown

Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III) (NEO-RIT)

Rectal Cancer

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Terminated

PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (PURO)

Urinary Bladder Cancer

Germany
WiSP Wissenschaftlicher Service Pharma GmbH
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Suspended

Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Germany
Palleos Healthcare GmbH
Pfizer; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP; AGO-TraFo; AGO-B; Deutsche...

Terminated

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

Breast Neoplasm

Germany

Clinical Trials Sponsored by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations